ISDA

Entry Detail

PDB ID:

4GS9

Keywords:

Title:

Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains in complex with an inactive benzoxadiazole antagonist

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2012-08-27

Release Date:

2013-04-03

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.72 Å

R-Value Free:

0.20

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Endothelial PAS domain-containing protein 1
Mutations:R247E
Chain IDs:A
Chain Length:117
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q99814 Pfam ID:PF14598

Protein Blast

Polymer Type:polypeptide(L)
Description:Aryl hydrocarbon receptor nuclear translocator
Mutations:E362R
Chain IDs:B
Chain Length:121
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P27540 Pfam ID:PF14598

Ligand Molecules

0XB

PE8

Primary Citation

Development of Inhibitors of the PAS-B Domain of the HIF-2 alpha Transcription Factor

Rogers, J.L, Bayeh, L, Scheuermann, T.H, Longgood, J, Key, J, Naidoo, J, Melito, L, Shokri, C, Frantz, D.E, Bruick, R.K, Gardner, K.H, Macmillan, J.B, Tambar, U.K.Show

J.Med.Chem. 56 1739 1747 (2013)

PMID: 23363003 DOI: 10.1021/jm301847z

Abstact

Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2α-ARNT heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2α-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.

Legend

Protein

Chemical

Disease

Primary Citation of related structures